A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Summary

A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.

Timeline

Start

2017-05-10

Primary completion

2025-02-11

Completion

2025-10-23

Outcome

Missed primary endpoint

registry analysis (superiority test); Pembrolizumab vs Placebo; p = 0.067; NCT02841748 ↗

Drugs

Indications